ISRCTN53375662
Active, not recruiting
未知
An observational retrospective cohort study describing clinical outcomes and utilization of healthcare resources among persons with COVID-19 in England, stratified by infection severity and selected comorbidities
AstraZeneca (United Kingdom)0 sites11,990,730 target enrollmentOctober 21, 2021
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- COVID-19 (SARS-CoV-2 infection)
- Sponsor
- AstraZeneca (United Kingdom)
- Enrollment
- 11990730
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
2023 Results article in https://pubmed.ncbi.nlm.nih.gov/38115964/ immunocompromised populations (added 08/01/2024)
Investigators
Eligibility Criteria
Inclusion Criteria
- •This study will include all subjects in England who were active in all datasets described above for at least 1 day during the COVID\-19 infection identification period
Exclusion Criteria
- •Current participant exclusion criteria as of 16/12/2022:
- •No general exclusion criteria will be applied for defining the overall study population.
- •Previous participant exclusion criteria:
- •Subjects will be excluded from this study if they have less than 12 months of baseline data prior to 1 September 2020
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing VaccineParotid Gland InfectionFeverNCT02901990Jiangsu Province Centers for Disease Control and Prevention7,901
Completed
Not Applicable
Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration TrainingImmune Thrombocytopenic PurpuraNCT02085993Amgen41
Active, not recruiting
Not Applicable
ASSESS-meso: a long-term study looking at people with mesothelioma (cancer of the outer lining of the lung) that will gather information on symptoms, disease processes and factors that affect survivalMesothelioma (cancer of the outer lining of the lung)CancerISRCTN61861764orth Bristol NHS Trust Research & Innovation Department700
Completed
Not Applicable
PREP (Pre-Exposure Prophylaxis) of COVID-19Immuno-DeficiencyCOVID-19NCT05461378Ghady Haidar138
Completed
Not Applicable
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and BoysHPV VaccineHPV InfectionHIV-1-infectionNCT04711265Kenya Medical Research Institute176